- Stocks
- Pharma & Healthcare
- Alkem Laboratories
Alkem Laboratories share price
NSE: ALKEMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Alkem Laboratories at a glance
Alkem Laboratories (NSE: ALKEM) closed at ₹4,972.00 on 22 Oct 2026, down 0.58% on the day. With a market capitalisation of ₹59,448 Cr, it ranks 170th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 25.8× trailing earnings, against a return on equity of 16.7% in FY26. Over the past year the share price has fallen 9.6%. Its 52-week range is ₹4,811.00 (22 Oct 2026) to ₹5,933.50 (13 Jan 2026); the last close is 16.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹3,603 Cr (+14.6% year on year) and net profit ₹252 Cr (−22.1%), on a consolidated basis. Promoters held 49.70% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹59,448 CrRank 170 on NSE
- P/E (trailing)
- 25.8×
- Price to book
- 4.59×FY26
- EPS (TTM)
- ₹192.51to Q4 FY26
- ROE
- 16.7%FY26
- ROCE
- 19.9%FY26
- Debt to equity
- 0.12FY26
- Net profit margin
- 16.0%FY26
- Book value / share
- ₹1,156.01FY26
- 52-week high
- ₹5,933.5013 Jan 2026
- 52-week low
- ₹4,811.0022 Oct 2026
- 1-year return
- −9.6%
- RSI (14-day)
- 36.4
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.58% | −4.3% | −7.4% | −10.8% | −9.6% |
Alkem Laboratories quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,032 Cr | ₹3,415 Cr | ₹3,374 Cr | ₹3,144 Cr | ₹3,371 Cr | ₹4,001 Cr | ₹3,737 Cr | ₹3,603 Cr |
| Revenue YoY | +2.2% | −0.7% | +1.5% | +7.1% | +11.2% | +17.2% | +10.7% | +14.6% |
| Net profit | ₹550 Cr | ₹702 Cr | ₹641 Cr | ₹323 Cr | ₹668 Cr | ₹780 Cr | ₹654 Cr | ₹252 Cr |
| Net profit YoY | +91.2% | +14.2% | +6.0% | +6.1% | +21.5% | +11.1% | +2.0% | −22.1% |
| Net margin | 18.1% | 20.6% | 19.0% | 10.3% | 19.8% | 19.5% | 17.5% | 7.0% |
| EPS | ₹45.60 | ₹57.60 | ₹52.34 | ₹25.57 | ₹55.56 | ₹63.99 | ₹53.19 | ₹19.77 |
Alkem Laboratories financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹8,865 Cr | ₹10,634 Cr | ₹11,599 Cr | ₹12,668 Cr | ₹12,965 Cr | — |
| Operating profit | ₹1,842 Cr | ₹1,859 Cr | ₹1,408 Cr | ₹2,145 Cr | ₹2,527 Cr | — |
| Net profit | ₹1,618 Cr | ₹1,680 Cr | ₹1,007 Cr | ₹1,811 Cr | ₹2,216 Cr | — |
| EPS (₹) | ₹133.00 | ₹138.00 | ₹82.00 | ₹150.00 | ₹181.00 | — |
| Cash from operations | ₹1,265 Cr | ₹1,111 Cr | ₹1,683 Cr | ₹1,948 Cr | ₹1,913 Cr | — |
| Total debt | ₹34 Cr | ₹9 Cr | ₹0 Cr | ₹40 Cr | ₹311 Cr | ₹492 Cr |
| Shareholders' equity | ₹7,377 Cr | ₹8,638 Cr | ₹9,045 Cr | ₹10,312 Cr | ₹11,985 Cr | ₹13,820 Cr |
Alkem Laboratories shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 55.13% | 53.04% | 51.20% | 51.20% | 51.20% | 49.70% |
| Foreign institutions | 9.41% | 9.11% | 9.48% | 9.97% | 10.16% | 10.42% |
| Domestic institutions | 19.42% | 21.80% | 21.93% | 21.54% | 21.40% | 22.63% |
| Non-institutions | 16.05% | 16.05% | 17.40% | 17.30% | 17.25% | 17.25% |
Alkem Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Alkem Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| GLENMARKGlenmark Pharmaceuticals | ₹2,196.40 | −0.16% | +16.4% | ₹61,983 Cr | 45.5 | — |
| ALKEMAlkem Laboratories | ₹4,972.00 | −0.58% | −9.6% | ₹59,448 Cr | 25.8 | — |
| ASTERDMAster DM Health | ₹647.20 | −0.46% | −5.5% | ₹56,415 Cr | 101.1 | — |
| FORTISFortis Healthcare | ₹720.15 | −0.67% | −33.5% | ₹54,368 Cr | 52.3 | — |
| BIOCONBiocon | ₹332.85 | −0.19% | −5.1% | ₹54,244 Cr | 117.6 | — |
| ABBOTINDIAAbbott India | ₹25,445.00 | −1.57% | −15.3% | ₹54,069 Cr | 34.8 | — |
| IPCALABIPCA Laboratories | ₹1,932.90 | +0.62% | +48.4% | ₹49,038 Cr | 43 | — |
Ask anything about Alkem Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against ALKEM's own history. Try: “Why has ALKEM moved over the last three months?” · “Backtest a 50-day moving-average crossover on ALKEM over five years” · “Compare ALKEM with GLENMARK on margins and valuation”
Frequently asked questions about Alkem Laboratories
What is the share price of Alkem Laboratories today?
Alkem Laboratories (NSE: ALKEM) last closed at ₹4,972.00 on 22 Oct 2026. Its 52-week high is ₹5,933.50 and its 52-week low is ₹4,811.00.
What is the market cap of Alkem Laboratories?
Alkem Laboratories' market capitalisation is ₹59,448 Cr (₹59,448 Cr) at the 22 Oct 2026 close, ranking 170th among the NSE companies Pivot tracks.
What is the P/E ratio of Alkem Laboratories?
Alkem Laboratories trades at a trailing P/E of 25.8. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 52.3.
What is the ROE and ROCE of Alkem Laboratories?
Return on equity was 16.7% in FY26 and return on capital employed was 19.9% in FY26 (consolidated figures).
Is Alkem Laboratories a debt-free company?
No. Alkem Laboratories' debt-to-equity ratio was 0.12 in FY26, with total debt of ₹492 Cr.
What were Alkem Laboratories' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Alkem Laboratories reported revenue of ₹3,603 Cr, +14.6% year on year, and net profit of ₹252 Cr, −22.1% year on year.
How has Alkem Laboratories stock performed over the last year?
Alkem Laboratories' share price has fallen 9.6% over the past year, −10.8% over three months and −7.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Alkem Laboratories?
As of 30 Jun 2026: promoters 49.70%, foreign institutions 10.42%, domestic institutions 22.63%, non-institutions 17.25%.
Who are Alkem Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Alkem Laboratories by market cap are Glenmark Pharmaceuticals, Aster DM Health, Fortis Healthcare, Biocon, Abbott India and IPCA Laboratories.
Is Alkem Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Alkem Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ALKEM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text